Close Menu

NEW YORK (GenomeWeb) — Evotec said today that it has entered into a drug-discovery alliance with biotech firm Celgene that will focus on targeted protein degradation.

Under the terms of the deal, the partners will use Evotec's Panomics platform — which integrates genomic, transcriptomic, and proteomic data for analysis with the company's PanHunter bioinformatic technology — to identify difficult-to-track drug targets.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

The Los Angeles Times reports that a case of the novel coronavirus making people ill in China has been reported in the US. 

A bipartisan group of senators has introduced a bill seeking increased funding for certain fields, including synthetic biology, ScienceInsider reports. 

Discover magazine writes that paleoproteomics is increasing being used in archaeology, paleoanthropology, and paleontology, including a recent study of a 6,000-year-old ring. 

In Nucleic Acids Research this week: mutagenic effects of ultraviolet "A" light, post-transcription effects of synonymous mutations, and more.